• Explore /
  • Poster
  • / A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

Abstract Poster

Authors

null

Deepak Kilari

Department of Medicine, Froedtert Cancer Center, Medical College of Wisconsin, Milwaukee, WI

Deepak Kilari , Aniko Szabo , Abhishek Tripathi , Asit K. Paul , Robert S. Alter , Kathryn A. Bylow , Ariel Ann Nelson , William A. Hall , Peter Langenstroer , Kenneth Jacobsohn , Brian I. Rini , Peter J. Van Veldhuizen , Scott Johnson , Nancy B. Davis , Chunkit Fung , Matthew I. Milowsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04289779

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4618)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4618

Abstract #

TPS4618

Poster Bd #

99a

Abstract Disclosures

Similar Posters

First Author: Deepak Kilari

First Author: Enrique Grande

First Author: Chiara Mercinelli

First Author: Benjamin L. Maughan